Skip to main content

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study - Clinical Trial

Joshua Meyer, MD

Study Summary

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

The main questions the study aims to answer are:

  • Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor?
  • Can ART help reduce the side effects that participants may experience during treatment?

Participants will:

  • Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning.
  • Have a tumor biopsy, which involves taking a small sample of tissue from the cancer.
  • Receive 5 radiation treatments every other day over a 2-week period.
  • Provide blood samples before, during, and after your radiation treatment.

Contact Us
About This Trial:

For more information about this and other studies and to inquire about eligibility, please call 215-214-1515 or fill out this form.

Protocol: 25-1011 / IRB25-1011

Phase: I

Investigator: Joshua Meyer, MD

Disease(s): Pancreas

Full description:

Visit ClinicalTrials.gov for a full clinical trial description

Location(s): Fox Chase Cancer Center at Cottman Ave

Inclusion Criteria

  • Patients must have locally advanced unresectable PDA. This includes the following- per NCCN criteria*:
    • Unreconstructible involvement with the superior mesenteric vein or portal vein due to tumor or bland thrombus OR
    • Solid tumor contact with greater than 180 degrees of the superior mesenteric artery or celiac artery OR
    • Solid tumor contact with the aorta OR
  • Patients with non-metastatic disease that is inoperable by virtue of the operation posing excessive risk to the patient
  • Eastern Cooperative Oncology Group, or ECOG, performance status 0-2

Exclusion Criteria

  • Patients who have had prior chemoradiation to an overlapping volume
  • Patients with Adenosquamous carcinoma of the pancreas
    • A history of ataxia telangiectasia or other documented history of radiation hypersensitivity. Includes both bi- and mono-allelic likely pathogenic or pathogenic ATM mutations (VUS is acceptable)

For more information about this and other studies and to inquire about eligibility, please call 215-214-1515.